Physician profile
Richard B Mccrary
NPI 1265547301
$3,658.38
in general payments reported to CMS, 2019-2025
23 companies · $557 in 2025
The $557 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $123 · 2021: $293 · 2022: $887 · 2023: $639 · 2024: $500 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,696.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $671.03 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $609.08 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $559.76 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Supernus Pharmaceuticals, INC. | $512.29 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $208.70 | 2019-2025 | Vaxneuvance, Rotateq, Vaxelis |
| Glaxosmithkline, LLC. | $161.84 | 2020-2025 | Bexsero, Pediarix, Rotarix |
| Sanofi Pasteur INC. | $139.11 | 2019-2025 | |
| Ptc Therapeutics, INC. | $128.75 | 2023 | Emflaza |
| Genzyme Corporation | $123.63 | 2022 | |
| Alexion Pharmaceuticals, INC. | $109.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $99.19 | 2020-2022 | |
| Pfizer INC. | $69.59 | 2022-2024 | |
| Adlon Therapeutics L.P. | $36.13 | 2019-2021 | |
| Neos Therapeutics, LP | $36.10 | 2019 | |
| Collegium Pharmaceutical, INC. | $35.14 | 2025 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $33.21 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.95 | 2025 | Oxlumo |
| Seqirus USA INC | $20.87 | 2025 | Flucelvax |
| Genentech USA, INC. | $18.90 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.74 | 2025 | Relexxii |
| Harmony Biosciences LLC | $17.62 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.05 | 2023 | Flumist Quadrivalent |
| Arbor Pharmaceuticals, INC. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Mccrary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.